Gates Foundation invests $140 million in HIV, AIDS preventative treatment

To help create a device that will prevent people from contracting HIV and AIDS, billionaire Bill Gates has invested $140 million in Intarcia Therapeutics, a pharmaceutical company based in Boston, according to an International Business Times story.

Intarcia developed a drug pump originally designed to deliver medicine to patients with type-two diabetes that can be implanted underneath the skin. But now the company plans to use the same technology to help patients from getting HIV and AIDS. The device would not cure those who already have the disease, just help prevent it from spreading.

The funds will be invested through the Bill and Melinda Gates Foundation, which gave $50 million in equity stakes to the company and provided $90 million in grants toward developing the device.

To read more about the investment and Intarcia’s device, follow the link below.

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.